What is the prevalence of 2q23.1 Microdeletion Syndrome?

2q23.1 Microdeletion Syndrome is an ultra-rare genetic condition, with fewer than 100 cases reported in global medical literature to date. Due to the rarity of 2q23.1 Microdeletion Syndrome, exact prevalence and incidence rates remain unknown, though it is considered significantly underdiagnosed in the general population.

Is 2q23.1 Microdeletion Syndrome common?

2q23.1 Microdeletion Syndrome is classified as an ultra-rare disorder. Because it is caused by a small deletion in the MBD5 gene region, many individuals may go undiagnosed or be misdiagnosed with more common developmental disorders. Data from the Orphanet Journal of Rare Diseases indicates that the true prevalence is likely much higher than the number of confirmed clinical cases reported, as many patients remain unidentified without specialized chromosomal microarray testing.

Does 2q23.1 Microdeletion Syndrome affect genders or ages differently?

Clinical reports suggest that 2q23.1 Microdeletion Syndrome affects both males and females, with no clear evidence of gender bias in inheritance or clinical severity. The condition is primarily identified in pediatric populations due to developmental delays, but it is a lifelong genetic condition that persists into adulthood. Key diagnostic features often noted in clinical literature include:

• Severe intellectual disability and speech impairment.


• Characteristic facial features (e.g., broad forehead, down-slanting palpebral fissures).


• Behavioral challenges, including sleep disturbances and autistic-like features.


• Seizures or epilepsy reported in a significant subset of patients.

Why is accurate data on 2q23.1 Microdeletion Syndrome hard to find?

The challenges in gathering epidemiological data for 2q23.1 Microdeletion Syndrome stem from its reliance on advanced genetic sequencing. While clinical literature provides limited numbers, our community at DiseaseMaps.org currently supports 4 individuals living with this diagnosis. This real-world data highlights the isolation families feel when navigating a condition that lacks large-scale population statistics.

Next steps

• Consult with a clinical geneticist to confirm a diagnosis via chromosomal microarray.


• Connect with the 2q23.1 Microdeletion Syndrome community on DiseaseMaps.org to share experiences.


• Register with global rare disease patient registries to help researchers improve prevalence data.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: 2q23.1 microdeletion syndrome (ORPHA:261230).


• NIH Genetic and Rare Diseases Information Center (GARD): MBD5-associated neurodevelopmental disorder.


• OMIM (Online Mendelian Inheritance in Man): #613769 (MBD5-Associated Neurodevelopmental Disorder).